Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...

TIVDAK, the only antibody-drug conjugate (ADC) therapy in cervical cancer, demonstrated promising benefits including a clinically meaningful improvement in overall survival (OS) in the pivotal ...

(RTTNews) - Zai Lab Limited (ZLAB) announced that China's National Medical Products Administration or NMPA has accepted the Biologics License Application or BLA for TIVDAK (tisotumab vedotin-tftv ...

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Based on topline data, ZLAB said Tivdak, an antibody-drug conjugate, cut mortality risk by 45% in Chinese patients who had previously received standard systemic therapies. The Shanghai-based ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.

With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab ...